VM-2500

VM-2500 is an investigational antiviral prodrug of tenofovir being developed by Viriom as a next-generation nucleos(t)ide reverse transcriptase inhibitor (NRTI) for the treatment of HIV-1 and hepatitis B virus (HBV) infections. It is designed as an oral prodrug that delivers tenofovir intracellularly, where the active tenofovir diphosphate competitively inhibits viral reverse transcriptase and acts as a DNA polymerase inhibitor, leading to chain termination during viral DNA synthesis. Viriom has positioned VM-2500 as a potentially best-in-class tenofovir prodrug intended to improve antiviral potency and safety relative to earlier tenofovir formulations, but the program has since been discontinued in development for hepatitis B and HIV indications.